Cargando…

An observational time and motion study of denosumab subcutaneous injection and zoledronic acid intravenous infusion in patients with metastatic bone disease: results from three European countries

PURPOSE: Denosumab (administered via subcutaneous injection) demonstrated superior efficacy versus the intravenously administered zoledronic acid in the prevention of skeletal-related events in an integrated analysis of three head-to-head phase III trials in patients with bone metastases secondary t...

Descripción completa

Detalles Bibliográficos
Autores principales: Body, Jean-Jacques, Gatta, Francesca, De Cock, Erwin, Tao, Sunning, Kritikou, Persefoni, Wimberger, Pauline, Mebis, Jeroen, Peeters, Marc, Pedrazzoli, Paolo, Caraceni, Augusto, Adamo, Vincenzo, Hechmati, Guy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5527062/
https://www.ncbi.nlm.nih.gov/pubmed/28429148
http://dx.doi.org/10.1007/s00520-017-3697-5
_version_ 1783252909287276544
author Body, Jean-Jacques
Gatta, Francesca
De Cock, Erwin
Tao, Sunning
Kritikou, Persefoni
Wimberger, Pauline
Mebis, Jeroen
Peeters, Marc
Pedrazzoli, Paolo
Caraceni, Augusto
Adamo, Vincenzo
Hechmati, Guy
author_facet Body, Jean-Jacques
Gatta, Francesca
De Cock, Erwin
Tao, Sunning
Kritikou, Persefoni
Wimberger, Pauline
Mebis, Jeroen
Peeters, Marc
Pedrazzoli, Paolo
Caraceni, Augusto
Adamo, Vincenzo
Hechmati, Guy
author_sort Body, Jean-Jacques
collection PubMed
description PURPOSE: Denosumab (administered via subcutaneous injection) demonstrated superior efficacy versus the intravenously administered zoledronic acid in the prevention of skeletal-related events in an integrated analysis of three head-to-head phase III trials in patients with bone metastases secondary to solid tumors. To date, no studies have evaluated treatment administration duration endpoints of these two agents. METHODS: A multinational, multi-site, observational time and motion study conducted in 10 day oncology units (DOUs) across Belgium, Germany, and Italy. Observations of process time included task time and active healthcare professional (HCP) time for pre-defined tasks. Patient time measurements included entering/exiting the DOU, treatment room, and treatment chair or examination table. RESULTS: A total of 189 patients were enrolled (82 received zoledronic acid and 107 received denosumab) and 238 observations were recorded (104 for zoledronic acid and 134 for denosumab). Mean total task time was reduced by 81% when denosumab was used versus zoledronic acid (8.4 versus 44.2 min; p < 0.0001; pooled analysis across all countries). Pooled estimates for active HCP time were 12.2 min for zoledronic acid and 6.9 min for denosumab (44% reduction; p < 0.0001). CONCLUSIONS: In the countries studied, using denosumab compared with zoledronic acid reduced total task time and active HCP time. Thus, HCPs have more time to dedicate to other patients or care activities. An ability to increase the volume of appointments within DOUs could reduce waiting lists in sites operating at full capacity and increase overall productivity and efficiency in hospital processes. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00520-017-3697-5) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5527062
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-55270622017-08-08 An observational time and motion study of denosumab subcutaneous injection and zoledronic acid intravenous infusion in patients with metastatic bone disease: results from three European countries Body, Jean-Jacques Gatta, Francesca De Cock, Erwin Tao, Sunning Kritikou, Persefoni Wimberger, Pauline Mebis, Jeroen Peeters, Marc Pedrazzoli, Paolo Caraceni, Augusto Adamo, Vincenzo Hechmati, Guy Support Care Cancer Original Article PURPOSE: Denosumab (administered via subcutaneous injection) demonstrated superior efficacy versus the intravenously administered zoledronic acid in the prevention of skeletal-related events in an integrated analysis of three head-to-head phase III trials in patients with bone metastases secondary to solid tumors. To date, no studies have evaluated treatment administration duration endpoints of these two agents. METHODS: A multinational, multi-site, observational time and motion study conducted in 10 day oncology units (DOUs) across Belgium, Germany, and Italy. Observations of process time included task time and active healthcare professional (HCP) time for pre-defined tasks. Patient time measurements included entering/exiting the DOU, treatment room, and treatment chair or examination table. RESULTS: A total of 189 patients were enrolled (82 received zoledronic acid and 107 received denosumab) and 238 observations were recorded (104 for zoledronic acid and 134 for denosumab). Mean total task time was reduced by 81% when denosumab was used versus zoledronic acid (8.4 versus 44.2 min; p < 0.0001; pooled analysis across all countries). Pooled estimates for active HCP time were 12.2 min for zoledronic acid and 6.9 min for denosumab (44% reduction; p < 0.0001). CONCLUSIONS: In the countries studied, using denosumab compared with zoledronic acid reduced total task time and active HCP time. Thus, HCPs have more time to dedicate to other patients or care activities. An ability to increase the volume of appointments within DOUs could reduce waiting lists in sites operating at full capacity and increase overall productivity and efficiency in hospital processes. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00520-017-3697-5) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2017-04-21 2017 /pmc/articles/PMC5527062/ /pubmed/28429148 http://dx.doi.org/10.1007/s00520-017-3697-5 Text en © The Author(s) 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Article
Body, Jean-Jacques
Gatta, Francesca
De Cock, Erwin
Tao, Sunning
Kritikou, Persefoni
Wimberger, Pauline
Mebis, Jeroen
Peeters, Marc
Pedrazzoli, Paolo
Caraceni, Augusto
Adamo, Vincenzo
Hechmati, Guy
An observational time and motion study of denosumab subcutaneous injection and zoledronic acid intravenous infusion in patients with metastatic bone disease: results from three European countries
title An observational time and motion study of denosumab subcutaneous injection and zoledronic acid intravenous infusion in patients with metastatic bone disease: results from three European countries
title_full An observational time and motion study of denosumab subcutaneous injection and zoledronic acid intravenous infusion in patients with metastatic bone disease: results from three European countries
title_fullStr An observational time and motion study of denosumab subcutaneous injection and zoledronic acid intravenous infusion in patients with metastatic bone disease: results from three European countries
title_full_unstemmed An observational time and motion study of denosumab subcutaneous injection and zoledronic acid intravenous infusion in patients with metastatic bone disease: results from three European countries
title_short An observational time and motion study of denosumab subcutaneous injection and zoledronic acid intravenous infusion in patients with metastatic bone disease: results from three European countries
title_sort observational time and motion study of denosumab subcutaneous injection and zoledronic acid intravenous infusion in patients with metastatic bone disease: results from three european countries
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5527062/
https://www.ncbi.nlm.nih.gov/pubmed/28429148
http://dx.doi.org/10.1007/s00520-017-3697-5
work_keys_str_mv AT bodyjeanjacques anobservationaltimeandmotionstudyofdenosumabsubcutaneousinjectionandzoledronicacidintravenousinfusioninpatientswithmetastaticbonediseaseresultsfromthreeeuropeancountries
AT gattafrancesca anobservationaltimeandmotionstudyofdenosumabsubcutaneousinjectionandzoledronicacidintravenousinfusioninpatientswithmetastaticbonediseaseresultsfromthreeeuropeancountries
AT decockerwin anobservationaltimeandmotionstudyofdenosumabsubcutaneousinjectionandzoledronicacidintravenousinfusioninpatientswithmetastaticbonediseaseresultsfromthreeeuropeancountries
AT taosunning anobservationaltimeandmotionstudyofdenosumabsubcutaneousinjectionandzoledronicacidintravenousinfusioninpatientswithmetastaticbonediseaseresultsfromthreeeuropeancountries
AT kritikoupersefoni anobservationaltimeandmotionstudyofdenosumabsubcutaneousinjectionandzoledronicacidintravenousinfusioninpatientswithmetastaticbonediseaseresultsfromthreeeuropeancountries
AT wimbergerpauline anobservationaltimeandmotionstudyofdenosumabsubcutaneousinjectionandzoledronicacidintravenousinfusioninpatientswithmetastaticbonediseaseresultsfromthreeeuropeancountries
AT mebisjeroen anobservationaltimeandmotionstudyofdenosumabsubcutaneousinjectionandzoledronicacidintravenousinfusioninpatientswithmetastaticbonediseaseresultsfromthreeeuropeancountries
AT peetersmarc anobservationaltimeandmotionstudyofdenosumabsubcutaneousinjectionandzoledronicacidintravenousinfusioninpatientswithmetastaticbonediseaseresultsfromthreeeuropeancountries
AT pedrazzolipaolo anobservationaltimeandmotionstudyofdenosumabsubcutaneousinjectionandzoledronicacidintravenousinfusioninpatientswithmetastaticbonediseaseresultsfromthreeeuropeancountries
AT caraceniaugusto anobservationaltimeandmotionstudyofdenosumabsubcutaneousinjectionandzoledronicacidintravenousinfusioninpatientswithmetastaticbonediseaseresultsfromthreeeuropeancountries
AT adamovincenzo anobservationaltimeandmotionstudyofdenosumabsubcutaneousinjectionandzoledronicacidintravenousinfusioninpatientswithmetastaticbonediseaseresultsfromthreeeuropeancountries
AT hechmatiguy anobservationaltimeandmotionstudyofdenosumabsubcutaneousinjectionandzoledronicacidintravenousinfusioninpatientswithmetastaticbonediseaseresultsfromthreeeuropeancountries
AT bodyjeanjacques observationaltimeandmotionstudyofdenosumabsubcutaneousinjectionandzoledronicacidintravenousinfusioninpatientswithmetastaticbonediseaseresultsfromthreeeuropeancountries
AT gattafrancesca observationaltimeandmotionstudyofdenosumabsubcutaneousinjectionandzoledronicacidintravenousinfusioninpatientswithmetastaticbonediseaseresultsfromthreeeuropeancountries
AT decockerwin observationaltimeandmotionstudyofdenosumabsubcutaneousinjectionandzoledronicacidintravenousinfusioninpatientswithmetastaticbonediseaseresultsfromthreeeuropeancountries
AT taosunning observationaltimeandmotionstudyofdenosumabsubcutaneousinjectionandzoledronicacidintravenousinfusioninpatientswithmetastaticbonediseaseresultsfromthreeeuropeancountries
AT kritikoupersefoni observationaltimeandmotionstudyofdenosumabsubcutaneousinjectionandzoledronicacidintravenousinfusioninpatientswithmetastaticbonediseaseresultsfromthreeeuropeancountries
AT wimbergerpauline observationaltimeandmotionstudyofdenosumabsubcutaneousinjectionandzoledronicacidintravenousinfusioninpatientswithmetastaticbonediseaseresultsfromthreeeuropeancountries
AT mebisjeroen observationaltimeandmotionstudyofdenosumabsubcutaneousinjectionandzoledronicacidintravenousinfusioninpatientswithmetastaticbonediseaseresultsfromthreeeuropeancountries
AT peetersmarc observationaltimeandmotionstudyofdenosumabsubcutaneousinjectionandzoledronicacidintravenousinfusioninpatientswithmetastaticbonediseaseresultsfromthreeeuropeancountries
AT pedrazzolipaolo observationaltimeandmotionstudyofdenosumabsubcutaneousinjectionandzoledronicacidintravenousinfusioninpatientswithmetastaticbonediseaseresultsfromthreeeuropeancountries
AT caraceniaugusto observationaltimeandmotionstudyofdenosumabsubcutaneousinjectionandzoledronicacidintravenousinfusioninpatientswithmetastaticbonediseaseresultsfromthreeeuropeancountries
AT adamovincenzo observationaltimeandmotionstudyofdenosumabsubcutaneousinjectionandzoledronicacidintravenousinfusioninpatientswithmetastaticbonediseaseresultsfromthreeeuropeancountries
AT hechmatiguy observationaltimeandmotionstudyofdenosumabsubcutaneousinjectionandzoledronicacidintravenousinfusioninpatientswithmetastaticbonediseaseresultsfromthreeeuropeancountries